A new biomarker for early diagnosis of intestinal ischemia

SAYENS



21 Août 2019

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

CONTEXT

The vital prognosis of intestinal ischemia (sharp increase in blood flow towards the digestive tract) largely depends on its rapid diagnosis (mortality rate from 60% to 80%). We have recently identified a natural hormone that significantly increases in patients suffering from intestinal ischemia. This discovery allowed the qualification of this hormone as an early biomarker of intestinal ischemia.

 

DESCRIPTION

The said marker presents the characteristics of an ideal biomarker: precocity, sensitivity, produced by the intestine and measurable in the bloodstream. Quantitative detection tests are already commercialized for research use only and could be extended to a new market: clinical diagnosis. A rapid and reliable prognosis of this pathology would allow a better management of patients with intestinal ischemia and would therefore increase their survival rate.

 

COMPETITIVE ADVANTAGES

  • Specifically early stages biomarker for intestinal ischemia
  • First reliable biomarkers of intestinal ischemia
  • More specific and sensitive than current used biomarkers
  • Already available for quantitative detection tests (for research use only)

 

MARKETS & APPLICATIONS

Health - diagnosis : 

  • clinical diagnosis of mesenteric ischemia
  • companion test associated with some therapies

 

DEVELOPMENT STAGE 

Clinical results : increased biomarker plasma levels were observed in a preclinical mouse model with intestinal ischemia - increased levels of said biomarker were also seen after generating experimentally intestinal ischemia in human

 

RESEARCH TEAM

Laboratory Lipids, Nutrition, Cancer University of Burgundy - INSERM

 

INTELLECTUAL PROPERTY

French patent filed on Sept. 20th, 2016, & PCT Extension on March 28th, 2017 (national phases ongoing: EU, US, CN, JP, CA)

 

TARGET PARTNERSHIP

Patent licensing

 

CONTACT 

Thomas BLUM

Business Developer

+33 (0)6 17 06 68 07

thomas.blum@sayens.fr

Download the offer Download the offer

Newsletter